A pyrosequencing assay for the quantitative methylation analysis of the PCDHB gene cluster, the major factor in neuroblastoma methylator phenotype

被引:28
作者
Banelli, Barbara [1 ]
Brigati, Claudio [1 ]
Di Vinci, Angela [1 ]
Casciano, Ida [1 ]
Forlani, Alessandra [1 ]
Borzi, Luana [1 ]
Allemanni, Giorgio [1 ]
Romani, Massimo [1 ]
机构
[1] Ist Nazl Ric Canc IST, Lab Tumor Genet & Epigenet, I-16132 Genoa, Italy
关键词
DNA methylation; epigenetics; methylator phenotype; neuroblastoma; protocadherin B; pyrosequencing; DNA METHYLATION; POOR-PROGNOSIS; HUMAN CANCER; CPG; RISK; HYPERMETHYLATION; TUMORS;
D O I
10.1038/labinvest.2011.169
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
100103 [病原生物学]; 100218 [急诊医学];
摘要
Epigenetic alterations are hallmarks of cancer and powerful biomarkers, whose clinical utilization is made difficult by the absence of standardization and of common methods of data interpretation. The coordinate methylation of many loci in cancer is defined as 'CpG island methylator phenotype' (CIMP) and identifies clinically distinct groups of patients. In neuroblastoma (NB), CIMP is defined by a methylation signature, which includes different loci, but its predictive power on outcome is entirely recapitulated by the PCDHB cluster only. We have developed a robust and cost-effective pyrosequencing-based assay that could facilitate the clinical application of CIMP in NB. This assay permits the unbiased simultaneous amplification and sequencing of 17 out of 19 genes of the PCDHB cluster for quantitative methylation analysis, taking into account all the sequence variations. As some of these variations were at CpG doublets, we bypassed the data interpretation conducted by the methylation analysis software to assign the corrected methylation value at these sites. The final result of the assay is the mean methylation level of 17 gene fragments in the protocadherin B cluster (PCDHB) cluster. We have utilized this assay to compare the methylation levels of the PCDHB cluster between high-risk and very low-risk NB patients, confirming the predictive value of CIMP. Our results demonstrate that the pyrosequencing-based assay herein described is a powerful instrument for the analysis of this gene cluster that may simplify the data comparison between different laboratories and, in perspective, could facilitate its clinical application. Furthermore, our results demonstrate that, in principle, pyrosequencing can be efficiently utilized for the methylation analysis of gene clusters with high internal homologies. Laboratory Investigation (2012) 92, 458-465; doi:10.1038/labinvest.2011.169; published online 12 December 2011
引用
收藏
页码:458 / 465
页数:8
相关论文
共 30 条
[1]
Abe M, 2005, CANCER RES, V65, P828
[2]
Identification of genes targeted by CpG island methylator phenotype in neuroblastomas, and their possible integrative involvement in poor prognosis [J].
Abe, Masanobu ;
Watanabe, Naoko ;
McDonell, Nathalie ;
Takato, Tsuyoshi ;
Ohira, Miki ;
Nakagawara, Akira ;
Ushijima, Toshikazu .
ONCOLOGY, 2008, 74 (1-2) :50-60
[3]
Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas [J].
Abe, Masanobu ;
Westermann, Frank ;
Nakagawara, Akira ;
Takato, Tsuyoshi ;
Schwab, Manfred ;
Ushijima, Toshikazu .
CANCER LETTERS, 2007, 247 (02) :253-258
[4]
Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma [J].
Alaminos, M ;
Davalos, V ;
Cheung, NKV ;
Gerald, WL ;
Esteller, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (16) :1208-1219
[5]
DNA methylation in neuroblastic tumors [J].
Banelli, B ;
Di Vinci, A ;
Gelvi, I ;
Casciano, I ;
Allemanni, G ;
Bonassi, S ;
Romani, M .
CANCER LETTERS, 2005, 228 (1-2) :37-41
[6]
Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors [J].
Banelli, B ;
Gelvi, I ;
Di Vinci, A ;
Scaruffi, P ;
Casciano, I ;
Allemanni, G ;
Bonassi, S ;
Tonini, GP ;
Romani, M .
ONCOGENE, 2005, 24 (36) :5619-5628
[7]
Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the SFN gene in advanced stage, high-risk, neuroblastic tumor patients [J].
Banelli, Barbara ;
Bonassi, Stefano ;
Casciano, Ida ;
Mazzocco, Katia ;
Di Vinci, Angela ;
Scaruffi, Paola ;
Brigati, Claudio ;
Allemanni, Giorgio ;
Borzi, Luana ;
Tonini, Gian Paolo ;
Romani, Massimo .
INTERNATIONAL JOURNAL OF CANCER, 2010, 126 (03) :656-668
[8]
REVISIONS OF THE INTERNATIONAL CRITERIA FOR NEUROBLASTOMA DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT [J].
BRODEUR, GM ;
PRITCHARD, J ;
BERTHOLD, F ;
CARLSEN, NLT ;
CASTEL, V ;
CASTLEBERRY, RP ;
DEBERNARDI, B ;
EVANS, AE ;
FAVROT, M ;
HEDBORG, F ;
KANEKO, M ;
KEMSHEAD, J ;
LAMPERT, F ;
LEE, REJ ;
LOOK, AT ;
PEARSON, ADJ ;
PHILIP, T ;
ROALD, B ;
SAWADA, T ;
SEEGER, RC ;
TSUCHIDA, Y ;
VOUTE, PA .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) :1466-1477
[9]
Action at a distance: epigenetic silencing of large chromosomal regions in carcinogenesis [J].
Clark, Susan J. .
HUMAN MOLECULAR GENETICS, 2007, 16 :R88-R95
[10]
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report [J].
Cohn, Susan L. ;
Pearson, Andrew D. J. ;
London, Wendy B. ;
Monclair, Tom ;
Ambros, Peter F. ;
Brodeur, Garrett M. ;
Faldum, Andreas ;
Hero, Barbara ;
Iehara, Tomoko ;
Machin, David ;
Mosseri, Veronique ;
Simon, Thorsten ;
Garaventa, Alberto ;
Castel, Victoria ;
Matthay, Katherine K. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (02) :289-297